Erste Asset Management’s Akero Therapeutics AKRO Stock Holding History

Erste Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-47,000	Closed	-$2.24M	–	600
2025 Q3	$2.24M	Hold	47,000	–	–	0.02%	340
2025 Q2	$2.64M	Hold	47,000	–	–	0.02%	361
2025 Q1	$2.01M	Hold	47,000	–	–	0.03%	309
2024 Q4	$1.33M	Hold	47,000	–	–	0.02%	361
2024 Q3	$1.33M	Hold	47,000	–	–	0.02%	360
2024 Q2	$1.1M	Hold	47,000	–	–	0.01%	366
2024 Q1	$1.15M	Hold	47,000	–	–	0.02%	358
2023 Q4	$1.13M	Buy	+47,000	New	+$927K	0.02%	366

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Erste Asset Management's AKRO Position: Q4 2025 in Review

Erste Asset Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 47,000 shares — an estimated $2.24M sold.

Erste Asset Management first reported a position in AKRO in Q4 2023 and held it in 8 quarters. The position peaked at $2.64M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Erste Asset Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Erste Asset Management sold 47,000 Akero Therapeutics shares in Q4 2025, an estimated $2.24M.
Erste Asset Management first reported a position in Akero Therapeutics in Q4 2023 and held it in 8 quarters.
Erste Asset Management's Akero Therapeutics position peaked at $2.64M in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Erste Asset Management's 13F filing for Q4 2025, filed 11 Feb 2026.